Future uncertain for active immunotherapies in AD – Part 1


View Part II

The recent failure of active immunotherapies targeting beta-amyloid in Alzheimer’s disease has dampened some of the initial enthusiasm for this approach. Development of AN1792, an active beta-amyloid vaccine, was terminated following the development of meningoencephalitis in 6% of vaccinated subjects. This complication was attributed to use of full-length beta-amyloid1-42.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page